Trial Profile
A study of alirocumab and ezetimibe in patients with atherosclerotic cardiovascular disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2016
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Ezetimibe (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Adverse reactions; Therapeutic Use
- 21 Dec 2016 New trial record
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association.